Owing to their inherent role in immunomodulation, concerns have long existed about the use of biologic therapies in patients with active tuberculosis (TB). Most guidelines currently list active TB as an absolute contraindication to the use of immunomodulatory therapies. Contrary to this, we present a case of a patient with active disseminated TB who was safely treated with the interleukin-17 inhibitor bimekizumab.
No takes yet. Share an insight, caveat, or question.
Koroneos et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: